NO943915L - Lymfocytt-aktiveringsantigen HB15, et medlem av immunoglobulin-superfamilien - Google Patents

Lymfocytt-aktiveringsantigen HB15, et medlem av immunoglobulin-superfamilien

Info

Publication number
NO943915L
NO943915L NO943915A NO943915A NO943915L NO 943915 L NO943915 L NO 943915L NO 943915 A NO943915 A NO 943915A NO 943915 A NO943915 A NO 943915A NO 943915 L NO943915 L NO 943915L
Authority
NO
Norway
Prior art keywords
lymphocyte activation
activation antigen
immunoglobulin superfamily
disclosed
expressed
Prior art date
Application number
NO943915A
Other languages
English (en)
Norwegian (no)
Other versions
NO943915D0 (no
Inventor
Thomas F Tedder
Liang-Ji Zhou
Original Assignee
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc filed Critical Dana Farber Cancer Inst Inc
Publication of NO943915D0 publication Critical patent/NO943915D0/no
Publication of NO943915L publication Critical patent/NO943915L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
NO943915A 1992-04-17 1994-10-14 Lymfocytt-aktiveringsantigen HB15, et medlem av immunoglobulin-superfamilien NO943915L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/870,029 US5316920A (en) 1992-04-17 1992-04-17 Lymphocyte activation antigen HB15, a member of the immunoglobulin superfamily
PCT/US1993/003577 WO1993021318A1 (en) 1992-04-17 1993-04-14 Lymphocyte activation antigen hb15, a member of the immunoglobulin superfamily

Publications (2)

Publication Number Publication Date
NO943915D0 NO943915D0 (no) 1994-10-14
NO943915L true NO943915L (no) 1994-12-09

Family

ID=25354648

Family Applications (1)

Application Number Title Priority Date Filing Date
NO943915A NO943915L (no) 1992-04-17 1994-10-14 Lymfocytt-aktiveringsantigen HB15, et medlem av immunoglobulin-superfamilien

Country Status (10)

Country Link
US (1) US5316920A (pt)
EP (1) EP0636176B1 (pt)
JP (2) JP3973167B2 (pt)
AT (1) ATE185600T1 (pt)
AU (1) AU685745B2 (pt)
BR (1) BR9306344A (pt)
CA (1) CA2118309C (pt)
DE (1) DE69326759T2 (pt)
NO (1) NO943915L (pt)
WO (1) WO1993021318A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5710262A (en) * 1992-04-17 1998-01-20 Dana-Faber Cancer Institute, Inc. Nucleic acid encoding HB15 polypeptides
US5534430A (en) * 1993-08-31 1996-07-09 Hitachi Chemical Company Limited Cell strain capable of multiplying an Epstein-Barr virus
WO1997029781A1 (en) * 1996-02-15 1997-08-21 Immunex Corporation Methods and compositions for modulating an immune response
US5849589A (en) * 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
WO1998023747A2 (en) * 1996-11-27 1998-06-04 Schering Corporation Isolated mammalian dendritic cell genes; related reagents
US6361939B1 (en) 1996-11-27 2002-03-26 Schering Corporation Isolated mammalian dendritic cell genes; related reagents
US6228640B1 (en) 1997-02-07 2001-05-08 Cem Cezayirli Programmable antigen presenting cell of CD34 lineage
US6977073B1 (en) 1997-02-07 2005-12-20 Cem Cezayirli Method for stimulating an immune response
US6251665B1 (en) 1997-02-07 2001-06-26 Cem Cezayirli Directed maturation of stem cells and production of programmable antigen presenting dentritic cells therefrom
US7229621B2 (en) 1998-10-20 2007-06-12 Torrey Pines Institute For Molecular Studies Method to enhance the immunogenicity of an antigen
US6210672B1 (en) 1998-10-20 2001-04-03 Torrey Pines Institute For Molecular Studies Topical immunostimulation to induce Langerhans cell migration
GB2370273A (en) * 2000-12-20 2002-06-26 Viaxxel Biotech Gmbh Compounds that affect CD83 expression
JP2005519586A (ja) * 2001-11-21 2005-07-07 セルテック アール アンド ディー， インコーポレイテッド Ｃｄ８３遺伝子産物を利用したサイトカイン・レベルの操作法
US20040185040A1 (en) * 2001-11-21 2004-09-23 Celltech R & D Limited Modulating immune responses
AU2002950779A0 (en) * 2002-08-15 2002-09-12 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland A method of immunomodulation
EP1422241A1 (en) 2002-11-19 2004-05-26 Alexander Steinkasserer Use of soluble forms of CD83 and nucleic acids encoding them for the treatment or prevention of diseases
WO2004048552A2 (en) * 2002-11-21 2004-06-10 Celltech R & D, Inc. Modulating immune responses
US9102726B2 (en) * 2002-12-04 2015-08-11 Argos Therapeutics, Inc. Nucleic acid of recombination expression vector encoding soluble forms of CD83, host cells transformed/transfected therewith and pharmaceutical compositions containing same
US7169898B2 (en) * 2002-12-04 2007-01-30 Alexander Steinkasserer Soluble CD83 proteins and use thereof for the treatment or prevention of a disease or medical condition caused by dysfunction or undesired function of a cellular immune response involving T cells
ES2526548T3 (es) 2006-08-18 2015-01-13 Argos Therapeutics, Inc. Uso de CD83 en terapias de combinación
BRPI0812534B1 (pt) 2007-06-15 2020-04-28 Optis Wireless Technology Llc aparelho de radiocomunicação e método paro espalhamento de sinal de resposta
CA2725198A1 (en) * 2008-05-23 2009-11-26 Argos Therapeutics, Inc. Novel soluble cd83 polypeptides, formulations and methods of use
US9840559B2 (en) 2013-02-01 2017-12-12 The Regents Of The University Of California Anti-CD83 antibodies and use thereof
WO2016061617A1 (en) 2014-10-23 2016-04-28 Dendrocyte Biotech Pty Ltd Cd83 binding proteins and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2010321C (en) * 1989-02-21 2004-04-06 Thomas F. Tedder Lymphocyte-associated cell surface protein
FR2656800B1 (fr) * 1990-01-08 1992-05-15 Roussy Inst Gustave Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques.
KR100206524B1 (ko) * 1990-07-13 1999-07-01 어니스트 엠. 해데드 씨디 53 세포 표면 항원 및 그를 암호화하는 재조합 디엔에이

Also Published As

Publication number Publication date
JP3973167B2 (ja) 2007-09-12
NO943915D0 (no) 1994-10-14
JP2007159580A (ja) 2007-06-28
CA2118309A1 (en) 1993-10-28
WO1993021318A1 (en) 1993-10-28
AU685745B2 (en) 1998-01-29
US5316920A (en) 1994-05-31
DE69326759D1 (de) 1999-11-18
AU4104893A (en) 1993-11-18
ATE185600T1 (de) 1999-10-15
DE69326759T2 (de) 2000-03-02
JPH09508781A (ja) 1997-09-09
EP0636176B1 (en) 1999-10-13
CA2118309C (en) 2000-06-13
EP0636176A1 (en) 1995-02-01
BR9306344A (pt) 1998-06-30

Similar Documents

Publication Publication Date Title
NO943915D0 (no) Lymfocyt-aktiveringsantigen HB15, et medlem av immunoglobulin-superfamilien
Germann et al. Interleukin‐12/T cell stimulating factor, a cytokine with multiple effects on T helper type 1 (Th1) but not on Th2 cells
Vercelli et al. Induction of human IgE synthesis requires interleukin 4 and T/B cell interactions involving the T cell receptor/CD3 complex and MHC class II antigens.
AU2349697A (en) Monoclonal antibodies against the interferon receptor with neutralizing activity against type I interferon
ATE309360T1 (de) Vaskularer endothelialer wachstumsfaktor 2
DK0489837T4 (da) Inhibering af lymfocytters adhæsion til vaskulært endotel under anvendelse af en hidtil ukendt interaktion mellem ekstracellulær matrixreceptor og ligand
DK1003552T3 (da) LO-CD2a-antistof og anvendelser deraf til inhibering af T-celle-aktivering og -proliferation
PL309637A1 (en) Diagnostic test and therapy for demyelination diseases such as multiple sclerosis
Heusser et al. New concepts of IgE regulation
EE9900146A (et) Lahustuvad lümfotoksiin-ß retseptorid, lümfotoksiini retseptori vastased antikehad ja lümfotoksiini ligandi vastased antikehad terapeutiliste agensitena immunoloogiliste haiguste raviks
Schwab et al. Defective expression of high affinity IL-2 receptors on activated T cells from aged humans
Samberg et al. Preferential expression of neo-CRP epitopes on the surface of human peripheral blood lymphocytes
Ferrer et al. Differential interleukin secretion by in vitro activated human CD45RA and CD45RO CD4+ T cell subsets
NO862097L (no) Monoklonale antistoffer for humane ikke-smaacelle lungekarsinoma.
Butcher et al. Flow cytometric studies of IL-4-stimulated expression of the CD25 antigen by quiescent human B lymphocyte subpopulations
Thirion et al. CD66a (CEACAM1) expression by mouse natural killer cells
Pollack et al. Inhibition of antibody-dependent cellular cytotoxicity by autologous lymph node cells
Poros et al. Expression of Helix pomatia (HP) haemagglutinin receptors on cytolytic lymphocytes activated in mixed cultures
DE69637943D1 (de) LO-CD2a Antikörper und deren Verwendung zur Hemmung der T-zellen Aktivierung und Proliferation
McGarvie et al. The effect of recombinant interleukin 4 upon protein kinase activities associted with murine and human B lymphocyte plasma membranes
Mosmann et al. Heterogeneity of mouse helper T cells and cross-regulation of TH1 and TH2 clones
Ezine et al. Haemopoiesis and early T-cell differentiation
Cambier et al. The effect of second signals on the induction of B cell tolerance: failure of helper T cells to block tolerance induction
Trail Canine T lymphocyte subpopulations defined by the expression of IgMFc and IgGFc receptors: factors influencing Fc receptor expression and alterations in T lymphocyte subpopulations in two models of canine disease.
Governa et al. Autoantibodies in 16 patients with extensive burns and a review of the literature